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ABSTRACT
The purpose of this article is to summarize the
current knowledge about treatment with oral
platelet inhibitors in patients with acute
coronary syndrome (ACS). Antiplatelet therapy
has been shown to improve the prognosis of
patients with ACS with ST segment elevation
myocardial infarction (STEMI) and non-ST
segment elevation ACS (NSTE-ACS). Aspirin
should be given with a loading dose of
250–500 mg, followed by 75–100 mg/day. Dual
antiplatelet therapy is recommended for all
patients with ACS for 12 months regardless of
the initial revascularization strategy.
Clopidogrel should be administered at first
medical contact in STEMI with a loading dose
of 600 mg. In patients with ACS and
percutaneous coronary intervention (PCI)
2 9 75 mg clopidogrel should be given daily
over 7 days, while in all other patients 75 mg
per day appears to be sufficient. The two newer
adenosine diphosphate-receptor antagonists
prasugrel and ticagrelor lead to a more rapid
and effective inhibition of platelet aggregation
compared with clopidogrel, which was
associated with an improved clinical outcome
in two large randomized studies. Prasugrel is
indicated in patients with ACS undergoing PCI
and was most effective in diabetics and in
patients with STEMI. In the recent TaRgeted
platelet Inhibition to cLarify the Optimal
strateGy to medicallY manage Acute Coronary
Syndromes trial in medically treated patients
with NSTE-ACS, prasugrel did not significantly
reduce ischemic events compared with
clopidogrel. Ticagrelor has been studied in the
whole spectrum of ACS patients and reduced
cardiovascular and total mortality in
comparison with clopidogrel. The greatest
benefit has been observed in patients with
planned conservative treatment and in
patients with impaired renal function.
Expanding antiplatelet therapy from dual to
triple therapy including a platelet thrombin
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receptor antagonist in the thrombin receptor
antagonist for clinical event reduction in acute
coronary syndrome trial was not associated with
a significant reduction in the primary combined
endpoint but an increase in bleeding
complications. However, in the Thrombin
Receptor Antagonist in Secondary Prevention
of atherothrombotic ischemic events study in
patients with prior myocardial infarction,
vorapaxar on top of standard antiplatelet
therapy was effective.




Despite an early invasive strategy and
revascularization therapy, mortality and
morbidity in patients with acute coronary
syndromes (ACS) with ST segment elevation
myocardial infarction (STEMI) and non-ST
segment elevation ACS (NSTE-ACS) remain
high. Antiplatelet therapy is a cornerstone of
acute and long-term therapy in patients with
ACS [1, 2]. Numerous trials have been
performed to determine the optimal timing,
optimal dose and optimal duration of various
combinations of antiplatelet drugs. This
manuscript summarizes the current status of
antiplatelet treatment in patients with ACS with
STEMI and NSTE-ACS.
ASPIRIN
Aspirin is one of the most frequently studied
drugs and has been shown to improve prognosis
in patients with STEMI and NSTE-ACS [3]. With
a loading dose of 250–500 mg (orally or, as
preferred in Europe, intravenously), inhibition
of the cyclooxygenase A and attenuation of
thromboxane A2 is achieved within minutes.
While in the US a maintenance dose of 325 mg
has been preferred, in most European countries
100 mg is the standard. In the large Clopidogrel
optimal loading dose Usage to Reduce Recurrent
EveNTs/Optimal Antiplatelet Strategy for
InterventionS (CURRENT-OASIS) 7 trial [4] a
dose of 75–100 mg was as effective as
300–325 mg with respect to ischemic events
after 30 days, but associated with a reduction in
minor bleedings (Table 1). It should be
acknowledged that patients in the CURRENT-
OASIS 7 trial were a low-risk group, indicated by
the low combined endpoint rate of 4.3% after
30 days [4]. Therefore, it cannot be ruled out
Table 1 Results of the CURRENT-OASIS 7 study [4]
Aspirin dose 75–100 mg 300–325 mg P value
Total group n = 12,579 n = 12,507 –




Stroke 0.5% 0.6% NS
Combined endpoint 4.4% 4.2% 0.6 (NS)
Major bleeding 2.3% 2.3% NS
Minor bleeding 4.4% 5.0% 0.04
Patients with PCI n = 8,639 n = 8,624








Major bleeding 1.3% 1.5% NS
CURRENT OASIS Clopidogrel optimal loading dose Usage to Reduce
Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS, CV
cardiovascular, NS nonsigniﬁcant, PCI percutaneous coronary intervention
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that higher doses of aspirin might be beneficial
in higher risk ACS populations. However, in the
majority of patients a maintenance dose of
75–100 mg aspirin is certainly sufficient.
ADENOSINE DIPHOSPHATE-
RECEPTOR ANTAGONISTS
Current guidelines recommend dual
antiplatelet therapy with aspirin and an
adenosine diphosphate (ADP)-receptor
antagonist after STEMI and NSTE-ACS [1, 2].
The ADP-receptor antagonist clopidogrel is
labeled in a loading dose of 300 mg and a
maintenance dose of 75 mg in patients with
NSTE-ACS. This recommendation is based on
the results of the Clopidogrel in Unstable
Angina to Prevent Recurrent Events (CURE)
trial [5]. However, a 600 mg loading dose is
associated with a faster onset and higher level of
platelet aggregation inhibition [6]. In the
already mentioned CURRENT-OASIS 7 trial,
the 600 mg loading dose followed by
2 9 75 mg daily over 7 days reduced ischemic
events in patients with ACS treated with
percutaneous coronary intervention (PCI),
compared with the standard dose [7]. In the
patients without PCI there was no benefit of the
double-dose clopidogrel [4] (Table 2).
The optimal timing of initiation of
clopidogrel therapy is still a matter of debate.
In patients with STEMI and planned primary
PCI the results of a small randomized trial [8]
and large registries [9] suggest that the loading
dose should be given at first medical contact,
preferably in the prehospital phase in the
ambulance. Since only very few patients with
STEMI will be referred for immediate coronary
artery bypass surgery, the risk of severe bleeding
is not significantly increased with the
prehospital loading dose.
Clopidogrel has several drawbacks: the
delayed onset of action, the large
interindividual variability in platelet response,
and its irreversible effect on platelet inhibition
[6]. The first two points are due to the two-stage
activation process of clopidogrel, involving a
number of cytochrome P450 isoenzymes, which
are susceptible to drug–drug interactions and
genetic polymorphisms. Patients with genetic
polymorphisms have a reduced or a lack of
metabolism of clopidogrel, and might therefore
be good candidates for treatment with newer
compounds [10].
Two new compounds, the nonreversible
thienopyridine prasugrel and the reversible
Table 2 Results of the CURRENT-OASIS 7 study






Total group n = 12,520 n = 12,566
CV death 2.2% 2.1% NS
Myocardial
infarction
2.2% 1.9% 0.09 (NS)
Stroke 0.5% 0.5% NS
Combined
endpoint
4.4% 4.2% 0.6 (NS)
Major bleeding 2.0% 2.5% 0.01
Patients with PCI n = 8,703 n = 8,560








Major bleeding 1.1% 1.6% 0.01
CURRENT-OASIS Clopidogrel optimal loading dose
Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet
Strategy for InterventionS, CV cardiovascular, NS
nonsigniﬁcant, PCI percutaneous coronary intervention
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cyclopentyl-triazolo-pyrimidine, ticagrelor, lead
to a faster and more potent ADP-receptor
inhibition, compared with clopidogrel [11, 12].
While prasugrel needs only one metabolization
step, ticagrelor is an active drug which does not
need metabolization to become active. In two
large trials they were compared with the
standard clopidogrel dose (300 mg loading
dose followed by 75 mg) and were able to
reduce the primary endpoint of cardiovascular
death, myocardial infarction, and stroke
significantly [13, 14] (Fig. 1). While the benefit
of prasugrel in the TRial to Assess Improvement
in Therapeutic Outcomes by Optimizing
Platelet InhibitioN (TRITON) with Prasugrel–
Thrombolysis In Myocardial Infarction (TIMI;
TRITON-TIMI 38) occurred early, the timing of
benefit with ticagrelor in the PLATelet
inhibition and patient Outcomes (PLATO) trial
was somewhat delayed, but constantly growing
over time.
There were important differences in design
and patients between the two trials. In TRITON-
TIMI 38 only ADP-receptor antagonist-naı¨ve
patients with NSTE-ACS and known coronary
artery anatomy undergoing PCI and patients
with STEMI scheduled for primary PCI were
included. In contrast, in the PLATO trial,
patients with the whole spectrum of ACS,
regardless of the initial strategy were enrolled.
Half of the patients were already pretreated with
clopidogrel. Therefore, the results of these two
trials cannot be compared directly. The 1-year
cardiovascular mortality was lower in TRITON-
TIMI 38 compared with PLATO (2.2% vs. 4.5%).
The PLATO trial included a higher-risk group of
ACS patients. However, in the PLATO trial
a significant reduction in cardiovascular
mortality (4.0% vs. 5.1%, P = 0.001) and all-
cause mortality (4.5% vs. 5.9%, P = 0.0003) was
observed. Patients with an impaired renal
function had particular benefit from ticagrelor
[15]. An important subgroup was the patients
undergoing coronary artery bypass surgery [16].
Here, ticagrelor reduced total mortality from
9.7% to 4.7% (P\0.01), without an increase in
major bleeding complications. Patients with an
intended conservative therapy also benefitted
from ticagrelor [14]. The question as to whether
ticagrelor should be given at first medical
contact in patients with STEMI scheduled for
primary PCI is currently being investigated in
the randomized Administration of Ticagrelor in
the Catheterization Lab or in the Ambulance for
New sT elevation myocardial Infarction to open
the Coronary artery (ATLANTIC) trial.
The results with prasugrel were particularly
impressive in patients with STEMI [17] and
with diabetes mellitus [18]. A subgroup in
which prasugrel was associated with an
unfavorable outcome are the patients with
prior stroke/transient ischemic attack (TIA). In
these patients, prasugrel is contraindicated.
Fig. 1 Incidence of the combined clinical endpoint of
cardiovascular death, myocardial infarction, and stroke in
large randomized clinical trials comparing oral antiplatelet
therapies in patients with acute coronary syndrome. APT
antiplatelet therapy, CURE clopidogrel in unstable angina
to prevent recurrent events trial, CV cardiovascular,
PLATO PLATelet inhibition and patient outcomes,
TRACER thrombin receptor antagonist for clinical event
reduction in acute coronary syndrome, TRITON-TIMI
TRial to Assess Improvement in Therapeutic Outcomes by
Optimizing Platelet InhibitioN with Prasugrel–Throm-
bolysis In Myocardial Infarction
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Elderly patients ([75 years of age) and patients
with lower body weight (\60 kg) had no
benefit, and an increase in bleeding
complications. It is likely that in these
patients a lower dose of 5 mg prasugrel would
be more appropriate. In the recently published
TaRgeted platelet Inhibition to cLarify the
Optimal strateGy to medicallY manage Acute
Coronary Syndromes (TRILOGY ACS) trial [19]
a reduction of the prasugrel dose to 5 mg in
the elderly and patients with a low body
weight was associated with a somewhat
higher but not statistically different bleeding
complication, compared with clopidogrel. In
this large clinical study, medically managed
patients with NSTE-ACS were randomized in
the subacute phase to prasugrel or clopidogrel.
The primary endpoint was not statistically
different between the two groups. However,
in patients with angiographically documented
coronary artery disease, prasugrel reduced the
combined endpoint from 16.5% to 12.8%
(P = 0.001). Another randomized study, A
Comparison of Prasugrel at PCI or Time of
Diagnosis of Non-ST Elevation Myocardial
Infarction: ACCOAST seeking to determine
the optimal timing of prasugrel in patients
with NSTE-ACS scheduled for coronary
angiography has been stopped prematurely,
due to an increase in bleedings in the
patients with a 30 mg loading dose before
angiography [20]. Therefore, the optimal
timepoint for administration of the loading
dose of prasugrel in NSTE-ACS seems to be
after visualization of coronary anatomy and
the decision to proceed to PCI.
Both studies have been criticized because of
the low loading dose of clopidogrel (300 mg),
which certainly is associated with a delayed
onset of action compared with the 600 mg dose
[6]. This applies somewhat more to the TRITON-
TIMI 38 study where all patients were ADP-
receptor antagonist naı¨ve. However, in the
CURRENT-OASIS 7 trial the differences
between the 300 and 600 mg loading dose
were overall statistically negative [3] and not
in the magnitude observed between prasugrel
and clopidogrel in the TRITON-TIMI 38 trial
[13]. In the ACAPULCO study, the 600 mg
loading dose of clopidogrel was not as
effective as prasugrel in patients with ACS
[11]. In the PLATO trial the benefit of
ticagrelor was somewhat delayed and the
curves continued to diverge during the follow-
up period, so a significant contribution of the
loading dose is unlikely. In addition, almost
half of the patients had received a clopidogrel
loading dose before randomization, and in
patients undergoing PCI an additional dose of
300 mg clopidogrel was given. The most recent
ACS European guidelines [1] recommend
clopidogrel only if prasugrel or ticagrelor are
not available, while the American guidelines do
not support the use of the new compounds so
strongly [2].
Elinogrel is a reversible ADP-receptor
antagonist which is available both in the
intravenous and oral form. Therefore, it seems
attractive for the treatment of ACS patients
avoiding the problem of oral application in the
acute phase, especially in patients who are not
able to digest drugs (postresuscitation,
intubation, vomiting, etc.). Elinogrel has been
studied in a small pilot trial in patients with
primary PCI for STEMI [21] and in a somewhat
larger phase 2 study in patients with elective
PCI [22]. Larger clinical trials are needed to
determine the value of this new compound.
In summary, the newer ADP-receptor
antagonists, prasugrel and ticagrelor, are able
to achieve a more rapid and effective inhibition
of platelet aggregation compared with
clopidogrel. This is associated with a 1.9–2.2%
absolute and 16–19% relative-risk reduction for
Cardiol Ther (2013) 2:47–56 51
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ischemic events, but with an increase of TIMI
major noncoronary artery bypass graft (CABG)-
related bleeding of 0.6%. Data looking at these
new compounds in patients with the need for
oral anticoagulation is lacking, therefore in
those patients clopidogrel should be given.
Other patient populations where we need
more data regarding safety and efficacy of the
new drugs are the elderly, patients with prior
stroke (especially hemorrhagic stroke), and
those with severe comorbidities, who were not
included in the large randomized trials. For
these patients, real-world data from large well-
performed registries are needed to determine
the safety and efficacy in clinical practice.
PLATELET THROMBIN RECEPTOR
ANTAGONISTS
One of the most potent activators of platelet
activation is thrombin. Thrombin activates
platelets through two protease-activated
receptors, PAR-1 and PAR-4. The inhibition of
the PAR-1 receptor has been found to result in
potent inhibition of thrombin-mediated
platelet activation but appears to preserve
primary hemostatic function [23]. Thus,
selective PAR-1 inhibitors seem attractive
substances for the treatment of patients with
ACS. Recently, the results of a large clinical trial
with vorapaxar, an oral PAR-1 antagonist, were
reported [23]. Patients with ACS\24 h duration
treated with standard therapy were given
vorapaxar or placebo, and followed for a mean
of 500 days. More than 98% of patients were on
aspirin and 91% received clopidogrel.
Therefore, this trial explored triple versus
double antiplatelet therapy. While the primary
endpoint of cardiac death, myocardial
infarction, stroke, rehospitalization, or urgent
coronary revascularization was not significantly
reduced (18.5% vs. 19.9%, P = 0.07), the main
secondary endpoint of cardiac death,
myocardial infarction, and stroke occurred
significantly less frequently with vorapaxar
(14.7% vs. 16.4%, P = 0.03) (Fig. 1). The rate of
TIMI major bleeding complications was
increased with vorapaxar (3.1% with vorapaxar
vs. 2.1% with placebo, P\0.01). In the
Thrombin Receptor Antagonist in Secondary
Prevention of atherothrombotic ischemic
events (TRA-2P) study in patients randomized
in the subacute or chronic phase after
myocardial infarction, vorapaxar reduced the
combined endpoint compared with placebo
from 9.7% to 8.1% (P\0.001) [24].
In summary, vorapaxar seems an attractive
new alternative in the spectrum of antiplatelet
agents used in patients with ACS. Further research
is needed to define the place of vorapaxar in the
treatment of ACS patients. So far, it is the only
antiplatelet therapy which has shown a benefit as
an add-on to aspirin [12 months after the acute
event [24]. In the acute and subacute phases it has
only been tested as add-on to dual antiplatelet
therapy; therefore, it would be of interest to
have a direct comparison with an ADP-receptor
antagonist in patients with a baseline therapy of
aspirin after ACS.
Another PAR-1 inhibitor, atopaxar, has been
studied in two small trials in patients with ACS
[25, 26]. It decreased ischemia on holter
monitoring and was associated with a
nonsignificant increase in the rate of major
TIMI bleeding complications [25]. So far, no
large clinical study has been performed with
this compound.
THE PROBLEM OF BLEEDING
DEFINITIONS
In recent years it has become clear that not only
the ischemic events but also bleeding
52 Cardiol Ther (2013) 2:47–56
123
contribute to the mortality of patients with
ACS. If antiplatelet treatment becomes more
intense and effective, this is usually associated
with an increase in bleeding complications. In
order to be able to compare the efficacy and
safety of new antiplatelet regimens, a unique
definition of bleeding complications would be
desirable [27]. Unfortunately, large clinical trials
have used different definitions for bleedings
[28]. In Table 3, bleeding complications in the
different large clinical trials with oral
antiplatelet therapy for ACS patients are
summarized.
In Fig. 2 the non-CABG-related major
bleeding rates after 30 days are depicted.
Looking at Table 3 and Fig. 2 it becomes clear
that the rate of CABG procedures and
the definition of bleeding complications
contribute majorly to the bleeding rates.
Therefore, it seems rather difficult to compare
bleeding complication rates between the trials.
The commonly used comparator therapy was
aspirin and the standard therapy was
clopidogrel (300/75 mg). With this therapy,
bleeding rates were by far not identical in the
trials, again underscoring the problems of
comparing therapies indirectly. Overall, the
results show that a more effective platelet
inhibition is associated with higher bleeding
rates.
Table 3 Bleeding complications in different trials with clopidogrel 300 mg loading dose and 75 mg maintenance dose as
comparator
CURE 9 months Placebo Clopidogrel 300 mg/75 mg P value
CURE bleeding 2.7% 3.7% \0.01
TIMI major bleeding 1.2% 1.1% NS
CURRENT-OASIS 7 30 days Clopidogrel 300 mg/75 mg Clopidogrel 600 mg/150 mg
CURRENT-OASIS 7 major 2.0% 2.5% \0.01
Non-CABG TIMI major 1.3% 1.7% \0.01
TRITON-TIMI 38 15 months Clopidogrel 300 mg/75 mg Prasugrel
TIMI major 1.9% 2.5% 0.03
Non-CABG TIMI major 1.8% 2.4% 0.03
PLATO 12 months Clopidogrel 300 mg/75 mg Ticagrelor
PLATO deﬁntion 11.2% 11.6% NS
Non-CABG TIMI major 2.0% 2.6% 0.02
TRACER Dual APT Dual APT ? vorapaxar
GUSTO severe or moderate 4.5% 6.1% \0.01
Non-CABG TIMI major 1.1% 2.0% \0.01
APT antiplatelet therapy, CABG coronary artery bypass graft, CURE Clopidogrel in Unstable Angina to Prevent Recurrent
Events trial, CURRENT-OASIS Clopidogrel optimal loading dose Usage to Reduce Recurrent EveNTs/Optimal
Antiplatelet Strategy for InterventionS, GUSTO, NS nonsigniﬁcant, PLATO PLATelet inhibition and patient Outcomes,
TIMI thrombolysis in myocardial infarction, TRACER Thrombin Receptor Antagonist for Clinical Event Reduction in
Acute Coronary Syndrome, TRITON-TIMI 38 TRial to Assess Improvement in Therapeutic Outcomes by Optimizing
Platelet InhibitioN with Prasugrel–Thrombolysis In Myocardial Infarction





There are numerous reports about the predictive
value of a high on-treatment platelet reactivity
in clopidogrel-treated patients for ischemic
events. However, trials aiming to adjust ADP-
receptor therapy with various platelet function
tests were all negative [29]. The most recent
one, the ARCTIC trial, measured platelet
function with the VeryNow AssayTM,
(Accumetrics, San Diego, CA, USA) in patients
undergoing PCI [29]. Adjustment of antiplatelet
therapy compared with standard treatment did
not reduce the primary ischemic endpoint or
bleeding complications. Therefore, so far there
seems to be no indication for the monitoring of
platelet function in patients treated with
various antiplatelet regimens.
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